DailyIQ
|
Sector:HealthcareAll sectors
Last updated6 minutes ago

RHHBY·Roche Holding AG

$53.77
-0.33 (-0.61%)
Overnight$53.77+0.00 (+0.00%)
High
$54.68
Open
$54.55
Market Cap
287.47B
52W High
$60.85
Low
$53.71
P. Close
$53.77
P/E
23.29
52W Low
$40.07
Fwd P/E
16.26
DailyIQ Est.
$60.40
Inst. Ownership
-
Short Interest
0.06%
Days to Cover
1.1
Div. Yield
2.96%
Next Ex-Div
~Mar 12
Technical Score (1D)
50
NEUTRAL
News Sentiment
70
BULLISH
On Oct 9, Genentech, a Roche Group subsidiary, received U.S. FDA approval for Tecentriq in combination with chemotherapy for stage III deficient DNA mismatch repair colon cancer. The approval was based on positive results from the Phase III ATOMIC study, which enrolled 712 patients and showed benefit when Tecentriq was added to standard FOLFOX6 chemotherapy. This regulatory decision expands Tecentriq’s U.S. indications, providing a new adjuvant treatment option after surgery for patients with DNA repair deficiency. The approval is expected to broaden Genentech’s market reach and enhance its oncology portfolio.
LOW TARGET
$52 -3.3%
3 analysts
MEAN TARGET
$60 +12.1%
16 analysts
HIGH TARGET
$67 +24.8%
9 analysts
PRICE RANGE
$52.00 - $67.10
SB / B / H / S / SS
5/8/11/3/1
DAILYIQ EST.
$60.40 (+12.3%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
OQX
Country
Switzerland
Website
roche.com
Symbol
RHHBY
Description
Roche Holding AG, established in 1896 and headquartered in Basel, Switzerland, is a global healthcare leader operating in the pharmaceuticals and diagnostics sectors. The company's core value proposition lies in its development of innovative pharmaceutical solutions, targeting a wide range of therapeutic areas including oncology, immunology, and neurological disorders. Complementing its pharmaceutical offerings, Roche provides a comprehensive suite of in vitro diagnostic tests and instruments, crucial for early disease detection and management across conditions like cancer and infectious diseases. This integrated approach, encompassing both therapeutic and diagnostic capabilities, positions Roche competitively in the healthcare market, enabling a holistic approach to patient care across numerous geographic regions, including Europe, North America, and Asia.
Earnings Summary
Roche Holding AG, a global healthcare leader established in 1896 and headquartered in Basel, Switzerland, operates significantly within the pharmaceuticals and diagnostics sectors. The company focuses on developing innovative treatments for oncology, immunology, and neurological disorders, complemented by a robust diagnostics division that aids in disease detection and management. This integrated approach positions Roche strongly within the competitive healthcare industry. Roche's recent financial performance shows a mixed trend. In Q1 2026, the company reported revenue estimates of $15.735 billion, though actual results were not provided. Looking back, the most recent reported quarters indicate a deceleration in revenue growth compared to the prior two periods, though specific figures for EPS and revenue actuals are not available for direct comparison. Historically, Roche has demonstrated a strong revenue growth trajectory year-over-year, driven by its pharmaceutical segment, particularly oncology therapies from Genentech. While specific beat/miss patterns against analyst estimates for EPS and revenue are not detailed in the provided data, the company's pipeline advancements suggest continued potential. Recent news highlights significant developments, including the "All Eyes on DME" campaign by Genentech to raise awareness for diabetic macular edema, potentially boosting demand for related treatments. Furthermore, Roche's experimental multiple sclerosis drug, fenebrutinib, has shown promising relapse reduction in Phase III trials, though safety concerns related to reported deaths warrant close monitoring. Advancements in Gazyva's application for lupus erythematosus and Enspryng's efficacy in MOGAD trials also point to future growth drivers. Investors will be watching for the impact of the DME awareness campaign on sales and any further regulatory developments or clarifications regarding the safety profile of fenebrutinib. Key will be the company's ability to translate pipeline successes into market share and sustained revenue growth, particularly in its core therapeutic areas.

EPS

EstBeatMiss
No data available
QtrEstActual+/−
Q1'26 - - -

Revenue

EstBeatMiss
$15.7B$15.7B$15.7B$15.7B$15.7BQ1'26
QtrEstActual+/−
Q1'26$15.7B - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RHHBY Stock Snapshot

NEUTRAL50/100
$53.77+$0.00 (0.0%)
Market cap
287.47B
P/E ratio
23.3
Day range
$53.71 – $54.68
News sentiment
70/100 · Bullish
Analyst target
$60.30 (+12.1%)
Consensus
Hold · 28 analysts
52-week range+34.2% off low · -11.6% from high
$40.07$60.85
Price $53.77 DailyIQ Est. $60.40

RHHBY is in a holding pattern - neither trend nor momentum has taken control. At this size, moves are driven by index flows and macro positioning as much as by company news.

Behaviour On Record

What RHHBY's own history says about today's numbers

Realized volatility (21d)
23.3% 76th pct
Below its peak
-10.7%
vs 200-day average
+1.6%
Up days (1y)
49%

Roche Holding AG is currently running 23.3% annualised volatility over the last 21 sessions. Measured against RHHBY's own 13 years of daily returns rather than a market-wide average, that is the 76th percentile — elevated for this stock, against a typical reading of 18.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RHHBY is trading -10.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.7%, and the deepest was -28.5% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +1.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 54th percentile — close to the gap it normally carries. Over the past year RHHBY closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, RHHBY finished the month higher 6 of 13 times, with a median return of -0.1% and an average of -1.7%. Its strongest month historically has been November at +2.3% on average, its weakest October at -1.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RHHBY has opened more than 2% away from the prior close in 208 of 3,266 sessions (6.4% of the time), with the largest gaps running +10.9% and -9.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against RHHBY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RHHBY's sector?

Roche Holding AG sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Pharmaceuticals industry group, RHHBY ranks 15th of 15 tracked industries, improving.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#15 of 15

Analyst Rating Changes

Are analysts turning bullish or bearish on RHHBY?

TD Cowen most recently reiterated its rating on Roche Holding AG to Market Perform on Sep 12, 2023 with a price target of $40 (from $45). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
TD Cowen — Market Perform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 12, 2023TD CowenMaintainedMarket Perform$45 → $40
Nov 15, 2022Cowen & Co.DowngradeOutperform → Market Perform$48
Jun 27, 2022Cowen & Co.MaintainedOutperform$58 → $48
Jul 8, 2021Deutsche BankUpgradeHold → Buy-
Jan 28, 2019Argus ResearchInitiatedBuy-
Jan 28, 2019Credit SuisseUpgradeUnderperform → Neutral-
Nov 19, 2018Goldman SachsDowngradeConviction Buy → Buy-
May 25, 2018Credit SuisseDowngradeNeutral → Underperform-
May 10, 2018BernsteinDowngradeOutperform → Market Perform-
Jan 8, 2015UBSDowngradeBuy → Neutral-
Mar 13, 2014Morgan StanleyInitiatedOverweight-
Aug 22, 2012JP MorganUpgradeNeutral → Overweight-

Peers & ETF holders

RHHBY peers & ETF holders

Drug Manufacturers - GeneralMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Roche, trading as RHHBY, announced a $100 million upfront payment to China‑based Rona Therapeutics for full ownership of an experimental RNA interference drug targeting ALK7. The agreement could total just over $1 billion if the therapy meets development, regulatory and commercial milestones. The deal adds a fifth China partnership in a short period and expands Roche’s obesity pipeline, positioning the company to compete with leading obesity drug makers.
What did this article say?
Roche (RHHBY) entered into an exclusive worldwide licensing agreement with Rona Therapeutics for an investigational ALK7‑targeting RNA interference therapy for obesity and metabolic diseases. The deal grants Roche rights to develop and commercialise the candidate using Rona’s extrahepatic delivery platform. Financial terms allow Rona to earn up to $1.16 billion in milestones, underscoring Roche’s commitment to expanding its obesity portfolio.
What did this article say?
Genentech, part of the Roche Group, reported that vamikibart produced rapid and sustained vision improvements and reduced macular thickness in Phase III MEERKAT and SANDCAT studies after 52 weeks. The results support the drug’s efficacy in treating uveitic macular edema. The FDA has accepted Genentech’s BLA, with an approval decision expected by July 2027.
What did this article say?
RHHBY reported that its investigational drug vamikibart achieved sustained vision improvements and reduced macular thickness in the Phase III MEERKAT and SANDCAT studies at 52 weeks. The data, presented at the AAO 2026 meeting, support continued progress toward FDA approval, which is expected by July 2027. The findings reinforce RHHBY’s position as a leader in treating uveitic macular edema, a leading cause of vision loss.
What did this article say?
On October 9, Roche’s Genentech, part of RHHBY, received FDA approval for Tecentriq combined with chemotherapy for stage III dMMR colon cancer. The approval follows Phase III ATOMIC trial data showing a 50% reduction in recurrence or death risk and a 10‑percentage‑point improvement in three‑year disease‑free survival. This marks the first approved adjuvant immunotherapy for this patient group, potentially expanding Tecentriq’s market share and strengthening RHHBY’s oncology portfolio.
What did this article say?
On October 9, 2026, Genentech, part of the Roche Group (RHHBY), announced FDA approval for Tecentriq combined with fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III deficient DNA mismatch repair colon cancer. The decision was based on the ATOMIC phase III study, which reported a 50% lower risk of recurrence or death compared to chemotherapy alone. The approval expands Tecentriq’s U.S. indications to twelve, reinforcing its position as a post‑surgery standard of care.
What did this article say?
Roche, trading under RHHBY, received FDA approval on October 9, 2026 for Tecentriq (atezolizumab) combined with fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer. The approval followed the ATOMIC phase III trial, which demonstrated a 50% reduction in recurrence or death versus chemotherapy alone. This marks the twelfth U.S. indication for Tecentriq and establishes it as a new post‑surgery standard of care for a significant subset of colon cancer patients.
What did this article say?
Roche received FDA approval for the Tecentriq and chemotherapy combination in stage III DMMR colon cancer based on the ATOMIC phase III trial. The study reported a 36‑month disease‑free survival rate of 86% for the combination versus 76% for chemotherapy alone. The approval was announced on October 8, 2024, following publication of the trial results in The New England Journal of Medicine. This regulatory milestone expands Roche’s oncology portfolio and could enhance future revenue streams.
What did this article say?
The FDA approved Pfizer’s Tukysa in combination with Roche’s RHHBY Herceptin and Perjeta for maintenance treatment of HER2‑positive breast cancer. The approval extends Tukysa’s use to the frontline setting, offering a chemotherapy‑free option after induction therapy. Phase III HER2CLIMB‑05 data showed a 35.9% reduction in risk of progression or death and an 8.6‑month improvement in median progression‑free survival. The decision strengthens RHHBY’s positioning in the HER2‑positive market and could drive future sales growth.

Technical Analysis

Real-time indicators across multiple timeframes

50
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Congressional Trading Activity
9 disclosed trades · ~$121.0K est. traded value · 4 buys, 5 sells
MemberChamberStateTypeAmountTradedFiled
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2018-04-242019-05-09
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2018-02-282018-03-08
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-09-082017-10-06
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-09-052017-10-16
Susan M. CollinsSenateME▼ Sell$15K - $50K2017-03-022017-04-11
Susan M. CollinsSenateME▲ Buy$15K - $50K2014-05-072014-05-16
Susan M. CollinsSenateME▲ Buy$1K - $15K2014-04-042014-04-08
View full congressional trading history →

Discover More

MDGL
Madrigal Pharmaceuticals Inc.
$452.12
+0.06%
CORT
Corcept Therapeutics Incorporated
$117.55
-0.20%
GILD
Gilead Sciences, Inc.
$148.01
+0.07%
HALO
Halozyme Therapeutics Inc.
$109.62
+0.00%
BMY
Bristol-Myers Squibb Company
$56.75
+0.11%
KYMR
Kymera Therapeutics Inc.
$106.68
-0.06%
USMV
iShares MSCI USA Min Vol Factor ETF
$100.62
+0.00%
ARGX
Argenx SE American Depositary Shares
$802.64
+0.04%
RGEN
Repligen Corporation
$175.42
+0.00%
TBXU
Direxion Daily Biotech Top 5 Bull 2X ETF
$37.00
+0.00%